| Sep 4 |
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
|
| Aug 27 |
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
|
| Aug 9 |
ALX Oncology GAAP EPS of -$0.76 in-line
|
| Aug 8 |
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Aug 6 |
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
|
| Aug 1 |
Dow Dips Over 500 Points; ISM Manufacturing PMI Falls In July
|
| Aug 1 |
Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients
|
| Aug 1 |
ALX Oncology’s evorpacept shows potential in Phase II gastric cancer trial
|
| Jul 31 |
ALX Oncology reports Phase 2 data for gastric cancer drug evorpacept
|
| Jul 31 |
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
|
